2024-2025 RSV Has Arrived - Why it Matters!
Why the Beyfortus Injection is Important for Infants
Beyfortus (nirsevimab) is a new, groundbreaking option for preventing severe RSV (Respiratory Syncytial Virus) infections in infants. Endorsed by trusted health organizations like the CDC, AAP, and Immunize.org, this antibody injection offers protection for babies during RSV season.
What Makes Beyfortus Important?
- Protects Against RSV: RSV is one of the leading causes of bronchiolitis and pneumonia in infants. Beyfortus provides crucial protection, especially for those too young to receive traditional vaccines.
- One Dose Protection: Unlike some treatments that require multiple doses, Beyfortus offers full protection in a single injection, making it easier for parents and caregivers to manage.
- Reduces Hospitalizations: Studies have shown that Beyfortus significantly reduces the risk of RSV-related hospitalizations, particularly for infants in their first year of life, who are most vulnerable to the virus.
- Recommended by Experts: Both the CDC and AAP recommend this antibody injection for infants, especially those born prematurely or with health conditions that put them at higher risk for severe RSV.
Who Should Receive Beyfortus?
- All infants under 8 months entering their first RSV season.
- High-risk infants (premature, lung/heart conditions) up to 24 months.
When and How?
Beyfortus is typically administered in the fall and protects throughout the RSV season. It can be given during routine appointments, so speak to us at your next appointment about whether your baby is a candidate for this protection.
For more details or to schedule an appointment, contact us at Einstein Pediatrics! We're here to help keep your little ones safe and healthy.




